Corcept Therapeutics Files Q1 2025 10-Q

Ticker: CORT · Form: 10-Q · Filed: May 5, 2025 · CIK: 1088856

Sentiment: neutral

Topics: 10-Q, pharmaceuticals, financials

TL;DR

Corcept Q1 2025 10-Q is in. Check financials.

AI Summary

Corcept Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The filing details the company's financial performance and position. Key financial data points such as revenue, net income, and cash flow from operations for the first quarter of 2025 are presented, alongside comparative figures from the prior year.

Why It Matters

This filing provides investors with the latest financial results and operational updates for Corcept Therapeutics, crucial for understanding the company's current health and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Corcept Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What were Corcept Therapeutics' total assets as of March 31, 2025?

The filing indicates financial data for the period ending March 31, 2025, but specific total asset figures are not detailed in the provided header information.

What is Corcept Therapeutics' primary business activity?

Corcept Therapeutics Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.

When was this 10-Q filing submitted to the SEC?

This 10-Q filing was submitted on May 5, 2025.

What is the fiscal year end for Corcept Therapeutics?

Corcept Therapeutics' fiscal year ends on December 31.

What is the company's principal executive office located?

The company's business address is 101 Redwood Shores Parkway, Redwood City, CA 94065.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 5, 2025 regarding CORCEPT THERAPEUTICS INC (CORT).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing